AtriCure/$ATRC
1D1W1MYTD1Y5YMAX
Capital at risk
About AtriCure
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation, Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.
- Ticker
- $ATRC
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 1,350
- Headquarters
- Mason, United States
- Website
- www.atricure.com
AtriCure Metrics
BasicAdvanced
$2.9B
266.56
$0.21
1.25
-
Price and volume
Market cap
$2.9B
Beta
1.25
52-week high
$61.70
52-week low
$25.36
Average daily volume
1.3M
Financial strength
Current ratio
4.218
Quick ratio
3.025
Long term debt to equity
0.138
Total debt to equity
0.144
Interest coverage (TTM)
2.19%
Profitability
EBITDA (TTM)
33.746
Gross margin (TTM)
76.30%
Net profit margin (TTM)
1.85%
Operating margin (TTM)
2.26%
Effective tax rate (TTM)
12.75%
Revenue per employee (TTM)
$420,000
Management effectiveness
Return on assets (TTM)
1.25%
Return on equity (TTM)
2.15%
Valuation
Price to earnings (TTM)
266.562
Price to revenue (TTM)
4.758
Price to book
5.3
Price to tangible book (TTM)
11.47
Price to free cash flow (TTM)
52.003
Free cash flow yield (TTM)
1.92%
Free cash flow per share (TTM)
1.081
Growth
Revenue change (TTM)
13.94%
Earnings per share change (TTM)
-127.45%
3-year revenue growth (CAGR)
15.92%
10-year revenue growth (CAGR)
14.86%
3-year earnings per share growth (CAGR)
-29.94%
10-year earnings per share growth (CAGR)
-15.67%
What the Analysts think about AtriCure
Analyst ratings (Buy, Hold, Sell) for AtriCure stock.
Analyst projections of the future price of AtriCure stock.
Bulls say / Bears say
AtriCure is delivering both growth and operating leverage. Q2 2026 revenue rose 12.8% to $153.6 million, gross margin reached 77.2%, and net income was $9.0 million; management guided to $602 million–$610 million revenue and $85 million–$89 million adjusted EBITDA for 2026. (Last10K)
The pipeline could expand AtriCure’s addressable market beyond today’s treated cardiac-surgery patients. BoxX-NoAF had enrolled more than 500 patients and was running ahead of plan, while LeAAPS had enrolled 6,573; positive results could support broader use and new product labelling. (StockAnalysis, MarketBeat)
Pain management is becoming a second growth engine, not just a cardiac add-on. Q2 US pain-management sales rose 27.8% to $27.1 million, and CryoXT gives AtriCure an early entry into amputation care where management sees further adoption potential. (Exa, StockAnalysis)
The minimally invasive ablation franchise is under pressure as catheter-based pulsed-field ablation gains ground. Q2 sales in that franchise fell to $6 million, so growth in pain management and open surgery must continue to offset a weakening business. (Exa)
Competition is intensifying in left atrial appendage management, historically a core AtriCure strength. Larger medtech groups including Boston Scientific, Abbott and Medtronic are entering or developing competing devices, which could bring pricing, bundling and market-share pressure. (AInvest, Last10K)
Pain-management adoption is not yet supported by US procedure reimbursement. Management said the products are currently not reimbursed in the US and that building the evidence for reimbursement could take years, leaving uptake dependent on hospitals and surgeons accepting the economic burden. (Exa, StockAnalysis)
Data summarised monthly by Lightyear AI. Last updated on 29 Sept 2026.
AtriCure Financial Performance
Revenues and expenses
AtriCure Earnings Performance
Company profitability
Upcoming events
No upcoming events
AtriCure News
AllArticlesVideos
Funds containing AtriCure
AllUSDEURGBP
Fund name | Fund size | $ATRC weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.30% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.30% |
iShares Healthcare Innovation£DRDR | £1B | 0.30% |
iShares Ageing Population€AGED | €822M | 0.26% |
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.17% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.